Will therapies that target tumour suppressor genes be useful in cancer treatment?

Advances in Clinical and Experimental Medicine

Volumn 22, Issue 6, 2013, Pages 861-864

  Szychot, Elwira ^a   Brodkiewicz, Andrzej ^b   Peregud Pogorzelski, Jarosław ^b  

^a Hospital for Children NHS Foundation Trust   (United Kingdom)

^b POMERANIAN MEDICAL UNIVERSITY   (Poland)

Author keywords

Cancer; Children; Genes; Leukaemia; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

CANCER MORTALITY; CANCER THERAPY; CHEMORADIOTHERAPY; GENE LOSS; GENE MUTATION; GENE TARGETING; HUMAN; MEDICAL SOCIETY; REVIEW; TUMOR SUPPRESSOR GENE; WILD TYPE;

ANIMALS; CHEMORADIOTHERAPY; GENES, P53; GENES, SUPPRESSOR; HUMANS; MUTATION; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84894182158     PISSN: 18995276     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. http://www.cancerresearchuk.org/cancer-info/cancerstats/incidence/ all-cancers-combined/
2. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100, 57-70. (Pubitemid 30046295)
3. Passioura T, Symonds G: Cancer gene suppression strategies: issues and potential. Curr Issues Mol Biol 2004, 6, 89-101.
4. Brummelkamp TR, Bernards R, Agami R: A system for stable expression of short interfering RNAs in mammalian cells. Science 2002, 296, 550-553. (Pubitemid 34408678)
5. Frezza C, Martins CP: From tumor prevention to therapy: Empowering p53 to fight back. Drug Resist Updat 2012, 15, 258-267.
6. Wang Z, Sun Y: Targeting p53 for novel anticancer therapy. Transl Biol 2010, 3, 1-12.
7. Wade M, Wang YV, Wahl GM: The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol 2010, 20, 299-309.
8. Hermeking H: MicroRNAs in the p53 network: micromanagement of tumour suppression. Nat Rev Cancer 2012, 12, 613-626.
9. Lambert JM, Gorzov P, Veprintsev DB, Söderqvist M, Segerbäck D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ: PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 2009, 15, 376-388.
10. Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature 2000, 408, 307-310.
11. Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA: A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 1993, 53, 4129-4133. (Pubitemid 24146752)
12. Secchiero P, Bosco R, Celeghini C, Zauli G: Recent advances in the therapeutic perspectives of Nutlin-3. Curr Pharm Des 2011, 17, 569-577.
13. Lowe SW, Sherr CJ: Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 2003, 13, 77-83. (Pubitemid 36143931)
14. Ringshausen I, O'Shea CC, Finch AJ, Swigart LB, Evan GI: Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006, 10, 501-514. (Pubitemid 44854749)